Abstract:PURPOSE:A new chemotherapy regimen was designed for leukemia to improve response to therapy and elucidate the possible underlying mechanisms responsible for its efficacy.METHODS:Cells of the chronic myelogenous leukemia (CML) cell line, K562, were treated singly, in combination, and in sequence with clinically equivalent dosages of topotecan, which targets topoisomerase I (Topo I), and etoposide and mitoxantrone, which target topoisomerase II (Topo II), to determine the best treatment. Apoptosis, early cell deaths, and cell cytotoxicities in drug-treated cells were determined with annexin V and propidium iodide staining and MTT assays, respectively. Confocal microscopy and RT-PCR showed the cellular locations and relative increases in Topo IIalpha in topotecan-treated cells. The double comet assay of individual cells showed simultaneously free Topo proteins, non-Topo-associated DNA, and Topo-DNA complexes in drug-induced DNA fragments.RESULTS:Sequential treatment with topotecan on days 1-3, followed by etoposide+mitoxantrone on days 4, 5, 9 and 10 resulted in 100% cell death whereas treatments involving administration of drugs singly or simultaneously resulted in less cell kill. The cytotoxicity results in cells treated for fewer days with the same sequential chemotherapy regimen showed the same trend, and adequate surviving cells for the experiments on the cellular and molecular mechanisms of drug action were produced. An increase in Topo IIalpha mRNA from RT-PCR 1 h after topotecan treatment was observed. Observations on K562 cells treated sequentially with topotecan followed by etoposide, mitoxantrone or etoposide+mitoxantrone were as follows: (1) Topo IIalpha protein levels increased and relocated from the cytoplasm into the nucleus as detected by confocal microscopy, (2) Topo IIalpha-DNA complexes increased and were associated with fragmented DNA (positive double comets) as detected by protein-DNA double comet assay, and (3) Topo I and Topo IIbeta proteins were not associated with fragmented DNA. Topotecan-induced Topo IIalpha protein levels correlated with increased numbers of positive double comets and reduction of cell viability.CONCLUSIONS:Our results showed that Topo IIalpha protein induction after Topo I-directed drug treatment enhanced the sensitivity of cells to subsequent exposure to Topo II-directed drugs. Timed sequential chemotherapy with topotecan followed by etoposide+mitoxantrone is an effective regimen to ablate CML cancer cells.

Etoposide: A rider on the cytokine storm

Etoposide Therapy of Cytokine Storm Syndromes

Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome

Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells

Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndrome–Hemophagocytic Lymphohistiocytosis

[High-Dose Etoposide with Granulocyte Colony-Stimulating Factor for Mobilization of Autologous Peripheral Blood Stem/progenitor Cells in Patients with Hematologic Malignancies].

Recent advances in the treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome

Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP2 poison anti‐cancer drug etoposide

Immediate severe hypersensitivity reaction to etoposide phosphate: Case report and review of the literature

Topotecan-induced Topoisomerase IIalpha Expression Increases the Sensitivity of the CML Cell Line K562 to Subsequent Etoposide Plus Mitoxantrone Treatment.

Patients with Hemophagocytic Lymphohistiocytosis Who Need Intensive Care Can Be Successfully Rescued by Timely Using Etoposide-Based HLH Regimens

Successful management of infection and macrophage activation syndrome patient using low-dose etoposide: A case report

Successful desensitization to etoposide in a patient after cardiac arrest

Altered Drug Interaction and Regulation of Topoisomerase IIbeta: Potential Mechanisms Governing Sensitivity of HL-60 Cells to Amsacrine and Etoposide.

Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations

Goodbye etoposide? Taking the leap to ruxolitinib in haemophagocytic lymphohistiocytosis

Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society

KCTD5 regulates Ikaros degradation induced by chemotherapeutic drug etoposide in hematological cells

The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor bearing mice

Pharmacokinetically Guided Phase I Trial of Topotecan and Etoposide Phosphate in Recurrent Ovarian Cancer

Efficacy and Safety of Oral Etoposide on Heavily Pretreated Metastatic Breast Cancer